tesaglitazar has been researched along with Diabetes Mellitus, Adult-Onset in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (71.43) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Henke, BR | 1 |
| Ahn, BN; Bae, MH; Chong, W; Han, T; Kim, E; Kim, EJ; Kim, JK; Kim, MK; Kim, SH; Lee, CH; Lim, JI; Moon, HS; Park, CS; Shim, HJ; Shin, CY; Shin, YA; Son, MH | 1 |
| Basu, S; Giri, S; Godha, A; Goel, A; Goswami, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Patil, P; Pingali, H; Shah, S; Zaware, P | 1 |
| Audinot-Bouchez, V; Boutin, JA; Caignard, DH; Dacquet, C; Guillard, J; Hennuyer, N; Ktorza, A; Parmenon, C; Staels, B; Viaud-Massuard, MC | 1 |
| Bakhti, M; Bastidas-Ponce, A; Baugé, E; Campbell, JE; Capozzi, M; Clemmensen, C; Collden, G; Cota, P; DiMarchi, RD; Douros, J; Drucker, DJ; DuBois, B; Feuchtinger, A; Finan, B; Garcia-Caceres, C; Grandl, G; Harger, A; Hennuyer, N; Herzig, S; Hofmann, SM; Klingelhuber, F; Knerr, PJ; Krahmer, N; Kulaj, K; Lalloyer, F; Lickert, H; Liskiewicz, A; Liskiewicz, D; Maity, G; Müller, TD; Novikoff, A; Perez-Tilve, D; Prakash, S; Quarta, C; Sanchez-Garrido, MA; Staels, B; Stemmer, K; Tschöp, MH; Yang, B; Zhang, Q | 1 |
| Area-Gomez, E; Chin, A; Civelek, M; Drosatos, K; Goldberg, IJ; Kalliora, C; Kyriazis, ID; Lieu, MJ; Madesh, M; Mizushima, W; Oka, SI; Pol, CJ; Sadoshima, J; Scerbo, D; Schulze, PC; Tian, Y; Yue, Y | 1 |
| Beck-Sickinger, AG; Blüher, M; Chakaroun, R; Klöting, N; Mörl, K; Wittrisch, S | 1 |
| Drosatos, K; Kalliora, C | 1 |
| Charbonnel, B | 1 |
| Hamrén, B; Karlsson, MO; Ribbing, J; Svensson, MK | 1 |
| Hamrén, B; Karlsson, MO; Ohman, KP; Svensson, MK | 1 |
| Lebovitz, H | 1 |
| Cox, SL | 1 |
| Fiévet, C; Fruchart, JC; Staels, B | 1 |
| Anzalone, D; Goldstein, BJ; Ohman, KP; Rosenstock, J; Tou, C | 1 |
| Bailey, CJ | 1 |
| Bays, H; Bryzinski, BS; McElhattan, J | 1 |
| Gause-Nilsson, I; Persson, A; Wilding, JP | 1 |
| Gause-Nilsson, I; Göke, B; Persson, A | 1 |
| Parikh, S; Ratner, RE; Tou, C | 1 |
| Björk, E; Hamrén, B; Karlsson, M; Sunzel, M | 1 |
5 review(s) available for tesaglitazar and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Signal Transduction; Thiophenes | 2020 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
Tesaglitazar: a promising approach in type 2 diabetes.
Topics: Alkanesulfonates; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Insulin Resistance; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Topics: Alkanesulfonates; Animals; Diabetes Mellitus, Type 2; Glycine; Humans; Metabolic Syndrome; Models, Biological; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
7 trial(s) available for tesaglitazar and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus.
Topics: Aged; Alkanesulfonates; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Models, Biological; Phenylpropionates; Pioglitazone; Thiazolidinediones | 2012 |
Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
Topics: Adult; Aged; Aged, 80 and over; Alkanesulfonates; Blood Glucose; Cholesterol, HDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Alkanesulfonates; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Phenylpropionates; Pioglitazone; Thiazolidinediones; Time Factors | 2007 |
Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Alkanesulfonates; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma; Sulfonylurea Compounds | 2007 |
The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes.
Topics: Adult; Aged; Alkanesulfonates; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma; Time Factors | 2007 |
Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Alkanesulfonates; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma; Time Factors; Triglycerides | 2007 |
Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment.
Topics: Adult; Aged; Aged, 80 and over; Alkanesulfonates; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Hemodilution; Hemoglobins; Humans; Hypoglycemic Agents; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma | 2008 |
9 other study(ies) available for tesaglitazar and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
Topics: Animals; Combinatorial Chemistry Techniques; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley | 2008 |
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
Topics: Animals; Carboxylic Acids; Diabetes Mellitus, Type 2; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Mesylates; Mice; Models, Chemical; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Transcriptional Activation | 2008 |
4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Mice; Oximes; PPAR alpha; PPAR gamma; Quinolines; Rats; Structure-Activity Relationship | 2009 |
GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice.
Topics: Alkanesulfonates; Animals; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Male; Mice; Obesity; Phenylpropionates; PPAR alpha | 2022 |
Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.
Topics: Alkanesulfonates; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Myocytes, Cardiac; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Peroxisomes; Phenylpropionates; PPAR alpha; PPAR gamma; Receptors, Leptin; Sirtuin 1; Transcription Factors; Transcriptome | 2019 |
NPY
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Alkanesulfonates; Animals; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; HEK293 Cells; Humans; Mice; Mice, Inbred C57BL; Molecular Conformation; Peptides; Phenylpropionates; PPAR alpha; PPAR gamma; Receptors, Neuropeptide Y; Structure-Activity Relationship | 2020 |
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Topics: Alkanesulfonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Thiophenes | 2009 |
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes.
Topics: Alkanesulfonates; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Fasting; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Models, Biological; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Predictive Value of Tests; Time Factors | 2010 |
Learning from tesaglitazar.
Topics: Alkanesulfonates; Diabetes Mellitus, Type 2; Humans; Models, Biological; Phenylpropionates; PPAR alpha; PPAR gamma | 2007 |